(A) ChIP analyses of FOXO1 binding to enhancers in the
Rag1/Rag2 locus. ChIP was performed with anti-FOXO1
antibody or an isotype IgG control antibody, followed by qPCR analysis of
FOXO1 binding to regulatory elements (ERAG1-ERAG3) in the
Rag1/Rag2 locus (39, 43, 48, 65) in Eμ-Myc
Cdk4–/– versus Eμ-Myc
Cdk4+/+ lymphoma. Results are the fold
enrichment in immunoprecipitates of FOXO1 antibody relative to control
antibody (mean and SD of triplicate ChIP; P < 0.01).
(B) Control of RAG1 and RAG2 expression by CDK4 is FOXO1
dependent. Eμ-Myc Cdk4–/–
lymphoma cells were transfected with siRNA targeting FOXO1 (FOXO1-RNAi), a
control siRNA (Ctrl RNAi), or a vector driving FOXO1 expression. Levels of
FOXO1, RAG1, RAG2, CDK4, and CDK2 proteins were determined by
immunoblotting. Note that FOXO1 knockdown reduced RAG1 and RAG2 levels,
whereas FOXO1 overexpression increased their levels. Results shown are
representative of three separate analyses. (C) FOXO1-mediated
induction of RAG1 and RAG2 in Eμ-Myc B cells requires
phosphorylation of S329 in FOXO1. Eμ-Myc
Cdk4+/+ lymphoma cells were cotransfected with siRNA
targeting FOXO1 and vectors expressing FOXO1-S329A or a wobble mutant of
FOXO1-329A (FOXO1-S329A-RE) resistant to the FOXO1 siRNA. Note that FOXO1
knockdown decreased RAG1 and RAG2 levels and that this was reversed by
expression of FOXO1-S329-RE. Immunoblotting with CDK4 and CDK2 showed equal
loading. Results are representative of three independent experiments. Graphs
display the median ± SD (n = 3; mean ± SD, with
error bar).